Research - FDA confirms that LDL-C remains a viable surrogate endpoint for cholesterol-lowering drugs. ETC-1002 does not need a cardiovascular outcomes study prior to approval, and -1002 should be … Continue Reading
PremiumRecap - Biotech has been in a funk for over a week now, though Friday finished strong. iShares’ NASDAQ Biotechnology ETF (IBB) has been stuck hovering just … Continue Reading
Read nowResearch - It’s been almost 30 years since the U.S. FDA approved the first statin to lower cholesterol, and the class remains the go-to therapy for treating hypercholesterolemia.
PremiumInsights - Sorrento Therapeutics (SRNE) has sold lead drug candidate Cynviloq to NantPharma, founded by healthcare entrepreneur & SRNE’s largest investor, Patrick Soon-Shiong, and a subsidiary of partner NantWorks. Sorrento … Continue Reading
Read nowResearch - Completing their IPO in September 2014 and raising $56 million, Affimed Therapeutics (AFMD) is a German clinical-stage biopharmaceutical company developing targeted cancer immunotherapies. Affimed’s product … Continue Reading
Read nowInsights - Aduro Biotech (ADRO) begins trading on Wednesday morning at 10:25 ET having completed a $119 million IPO that values the immunotherapy company at just over … Continue Reading
Read now
